PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 2, 2019Journal of Medical Internet Research7 citationsOpen Access

QardioArm Upper Arm Blood Pressure Monitor Against Omron M3 Upper Arm Blood Pressure Monitor in Patients With Chronic Kidney Disease: A Validation Study According to the European Society of Hypertension International Protocol Revision 2010

VMVictoria Mazoteras‐PardoRVRicardo VallejoMLMarta Elena Losa‐Iglesias

Structured PICO

Does the QardioArm mobile device accurately measure blood pressure compared to the Omron M3 device in patients with chronic kidney disease?

P
Population
33 patients with chronic kidney disease
I
Intervention
Blood pressure self-measurement using the QardioArm mobile device (wireless upper arm oscillometric device connected to an app)
C
Comparator
Blood pressure measurement using the Omron M3 Intellisense device
O
Outcome
Validation of blood pressure measurement (systolic BP, diastolic BP, and heart rate) according to European Society of Hypertension International Protocol 2 (ESH-IP2) guidelinessurrogate

The QardioArm mobile device is a valid tool for blood pressure self-measurement in patients with chronic kidney disease, meeting ESH-IP2 requirements.

Abstract

BACKGROUND: Hypertension is considered as a main risk factor for chronic kidney disease development and progression. Thus, the control and evaluation of this disease with new software and devices are especially important in patients who suffer from chronic kidney disease. OBJECTIVE: This study aimed to validate the QardioArm mobile device, which is used for blood pressure (BP) self-measurement in patients who suffer from chronic kidney disease, by following the European Society of Hypertension International Protocol 2 (ESH-IP2) guidelines. METHODS: A validation study was carried out by following the ESH-IP2 guidelines. A sample of 33 patients with chronic kidney disease self-measured their BP by using the QardioArm and Omron M3 Intellisense devices. Heart rate (HR), diastolic BP, and systolic BP were measured. RESULTS: The QardioArm fulfilled the ESH-IP2 validation criteria in patients who suffered from chronic kidney disease. CONCLUSIONS: Thus, this study is considered as the first validation using a wireless upper arm oscillometric device connected to an app to measure BP and HR meeting the ESH-IP2 requirements in patients who suffer from chronic kidney disease. New validation studies following the ESH-IP2 guidelines should be carried out using different BP devices in patients with specific diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mazoteras‐Pardo et al. (2019) studied this question.

synapsesocial.com/papers/6a74383dc64913a07da7f6fahttps://doi.org/10.2196/14686
Ask AI
Helpful
Bookmark
Share
View Full Paper